Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | ARC-02 |
| Synonyms | |
| Therapy Description |
ARC-02 is an antibody-drug conjugate (ADC) comprising an antibody targeting CD79b conjugated to MMAE, which potentially inhibits growth of CD79b-expressing tumors (Blood (2022) 140 (Supplement 1): 11568-11569). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| ARC-02 | ARC02|ARC 02 | ARC-02 is an antibody-drug conjugate (ADC) comprising an antibody targeting CD79b conjugated to MMAE, which potentially inhibits growth of CD79b-expressing tumors (Blood (2022) 140 (Supplement 1): 11568-11569). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT07691606 | Phase I | ARC-02 ARC-02 + Rituximab | A Study of ARC-02 in B-cell NHL (ABLATE-101) | Recruiting | USA | POL | ITA | FRA | ESP | AUS | 0 |